key: cord-0924286-ifudkq7u
authors: Rocco, Patricia R. M.; Silva, Pedro L.; Cruz, Fernanda F.; Tierno, Paulo F. G. M. M.; Rabello, Eucir; Junior, Jéfiton Cordeiro; Haag, Firmino; de Ávila, Renata E.; da Silva, Joana D. G.; Mamede, Mariana M. S.; Buchele, Konrad S.; Barbosa, Luiz C. V.; Cabral, Anna C.; Junqueira, Antônio A. F.; Araújo-Filho, João A.; da Costa, Lucianna A. T. J.; Alvarenga, Pedro P. M.; Moura, Alexandre S.; Carajeleascow, Ricardo; de Oliveira, Mirella C.; Silva, Roberta G. F.; Soares, Cynthia R. P.; Fernandes, Ana Paula S. M.; Fonseca, Flavio Guimarães; Camargos, Vidyleison Neves; Reis, Julia de Souza; Franchini, Kleber G.; Luiz, Ronir R.; Morais, Sirlei; Sverdloff, Carlos; Martins, Camila Marinelli; Felix, Nathane S.; Mattos-Silva, Paula; Nogueira, Caroline M. B.; Caldeira, Dayene A. F.; Pelosi, Paolo; Lapa-e-Silva, José R.
title: Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
date: 2022-04-13
journal: Front Med (Lausanne)
DOI: 10.3389/fmed.2022.844728
sha: e5547bed3d2b8cf863f81e98024397435143a05a
doc_id: 924286
cord_uid: ifudkq7u

BACKGROUND: Nitazoxanide exerts antiviral activity in vitro and in vivo and anti-inflammatory effects, but its impact on patients hospitalized with COVID-19 pneumonia is uncertain. METHODS: A multicentre, randomized, double-blind, placebo-controlled trial was conducted in 19 hospitals in Brazil. Hospitalized adult patients requiring supplemental oxygen, with COVID-19 symptoms and a chest computed tomography scan suggestive of viral pneumonia or positive RT-PCR test for COVID-19 were enrolled. Patients were randomized 1:1 to receive nitazoxanide (500 mg) or placebo, 3 times daily, for 5 days, and were followed for 14 days. The primary outcome was intensive care unit admission due to the need for invasive mechanical ventilation. Secondary outcomes included clinical improvement, hospital discharge, oxygen requirements, death, and adverse events within 14 days. RESULTS: Of the 498 patients, 405 (202 in the nitazoxanide group and 203 in the placebo group) were included in the analyses. Admission to the intensive care unit did not differ between the groups (hazard ratio [95% confidence interval], 0.68 [0.38–1.20], p = 0.179); death rates also did not differ. Nitazoxanide improved the clinical outcome (2.75 [2.21–3.43], p < 0.0001), time to hospital discharge (1.37 [1.11–1.71], p = 0.005), and reduced oxygen requirements (0.77 [0.64–0.94], p = 0.011). C-reactive protein, D-dimer, and ferritin levels were lower in the nitazoxanide group than the placebo group on day 7. No serious adverse events were observed. CONCLUSIONS: Nitazoxanide, compared with placebo, did not prevent admission to the intensive care unit for patients hospitalized with COVID-19 pneumonia. CLINICAL TRIAL REGISTRATION: Brazilian Registry of Clinical Trials (REBEC) RBR88bs9x; ClinicalTrials.gov, NCT04561219.

COVID-19 is a multiple organ disease (1); patients presenting with moderate to severe symptoms may require intensive care unit (ICU) admission (2, 3). To date, pharmacological therapies with antiviral properties have presented modest results (4) (5) (6) . Nitazoxanide has shown antiviral and anti-inflammatory effects (7) (8) (9) (10) . In mild COVID-19, nitazoxanide significantly reduced the viral load with no serious adverse events (7) . More recently, a randomized, double-blind placebo-controlled clinical trial provides evidence that treatment of outpatients with mild or moderate COVID-19 with nitazoxanide may reduce the progression to severe illness, thus suggesting larger trials with adequate statistical power to confirm this hypothesis (11) . Nitazoxanide and its metabolite (tizoxanide) decreased inflammation in vitro and in vivo (8, 9) . Nitazoxanide alone reduced the duration of symptoms in patients with acute uncomplicated influenza (12) . In a proof-of-concept pilot trial, nitazoxanide decreased the mean time to hospital discharge, viral load, and inflammatory mediators in patients with COVID-19 (10) . Moreover, nitazoxanide is available at low cost particularly in low-and middle-income countries. We hypothesized that nitazoxanide could effectively reduce the number of patients with COVID-19 pneumonia admitted to the ICU due to the need for invasive mechanical ventilation. Secondary outcomes included clinical improvement, time to hospital discharge, oxygen requirements, death, radiological and laboratory findings, and adverse events during hospitalization until day 14. 

Consecutive adult patients (≥18 years), requiring supplemental oxygen (peripheral oxygen saturation [SpO 2 ] < 93%) and admitted to hospital with COVID-19 symptoms associated with a chest computed tomography (CT) findings suggestive of viral pneumonia or a positive nasopharyngeal swab test for SARS-CoV2 (RT-PCR) were eligible for inclusion. The inclusion and exclusion criteria are listed in the Supplementary Material.

With the aid of a computer-generated random number list, patients were randomly assigned (1:1) to receive placebo or nitazoxanide [500 mg oral solution, 20 mg/ml (25 ml), three times daily for 5 days], dispensed by the pharmacist at each hospital. Patients, treating clinicians, trial personnel, and outcome assessors were blinded to group assignment. Placebo and nitazoxanide were color-matched to ensure that assessors were unaware of the group allocation at all times (see the Supplementary Material for additional details regarding the trial design).

On day 1 (baseline), patients were assessed for eligibility. Written informed consent was obtained from all patients or from a legal representative (Supplementary Material). A nasopharyngeal swab was collected for RT-PCR testing. Site investigators performed a comprehensive physical examination, recording levels and type of oxygen supplementation and concomitant medications. Blood samples were taken (Supplementary Material). Adverse events, regardless of severity, were monitored throughout the trial by reviewing the electronic medical records, physical examination findings, vital signs, and laboratory tests from enrolment until day 14. Study data were entered directly into electronic case-report forms (REDCap) (14) and clinical trial management system (ATCGen) by the site investigator and validated by monitoring staff from ATCGen.

The primary outcome was ICU admission due to the need for invasive mechanical ventilation at any point during hospitalization until day 14.

The key secondary outcome measure was clinical status assessed daily according to an 8-point ordinal scale until day 14 (15) using the following categories: (1) not hospitalized, no limitation of activities; (2) not hospitalized, limitation of activities; (3) hospitalized, not requiring supplemental oxygen or ongoing medical care (used if hospitalization was extended for infectioncontrol reasons); (4) hospitalized, not receiving supplemental oxygen, but requiring ongoing medical care (COVID-19related or other medical conditions); (6) hospitalized, receiving supplemental oxygen; (6) hospitalized, receiving high-flow oxygen through a nasal cannula; (7) hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (8) death. Time to recovery was defined as the period from beginning of therapy to discharge from the hospital over a 14-day follow-up.

Additional secondary outcomes included (1) the proportion of patients with clinical improvement [time to improve two categories on the aforementioned 8-point ordinal scale of clinical status at baseline (day 1), and on days 3, 5, 7, and 14];

(2) the number of patients discharged (ordinal scale 1-2); (3) oxygen requirement (ordinal scale 5-6); (4) the number of deaths (ordinal scale 8) from randomization until day 14; (5) duration of symptoms suggestive of COVID-19, including dry cough, productive cough, sore throat, and shortness of breath; (6) number of patients with negative RT-PCR test on day 7 and percentage reduction in viral RNA load on nasopharyngeal swab specimens (from day 1 until day 7); (7) clinical (body temperature, respiratory rate, and SpO 2 ) and laboratory data (hemoglobin levels, WBC count, neutrophils, lymphocytes, platelets, C-reactive protein, D-dimer, ferritin, lactate dehydrogenase); (8) chest CT score (0-25%, 26-50%, 51-75%, and 76-100% of lung tissue compromised).

The statistical analysis plan was completed before the end of the study and unblinding of the study results and is available in the Supplementary Material.

Around 15% of patients hospitalized with COVID-19 were admitted to the ICU in March 2020. If 5% of hospitalized patients treated with nitazoxanide would be admitted to the ICU, with an alpha error of 5%, a statistical power of 90%, and two-tailed test, 198 participants per group would be required. Estimating a dropout rate of about 20%, our target sample size was set at 247 participants/group, which made up the intention-to-treat [ITT] population.

Descriptive statistics were used for demographic, laboratory, and clinical data. Fisher's exact test was used for qualitative variables. The Mann-Whitney U test or Student's t-test was used for comparisons between groups.

To evaluate the response to nitazoxanide, we separated the patients into three different groups: (1) ITT: the intention-totreat population, all eligible patients, (2) mITT: the modified intention-to-treat population (ITT population fully treated who completed the 14-day analysis), and (3) the mITT-positive population (patients who completed the 14-day analysis and had a positive nasopharyngeal swab RT-PCR test for SARS-CoV2). Patients who dropped out or died were included in the ITT population, but not in the mITT or mITTpositive population. Safety analyses were done in the ITT and mITT populations.

For the primary outcome, the odds ratio (OR) was derived from a mixed-effect ordinal logistic regression, assuming proportional ORs, adjusted for age, sex, body mass index (BMI), and time from symptom onset to randomization. The Kaplan-Meier method was used for time-to-event analyses and compared with a log-rank test. The hazard ratios (HRs) and 95% confidence intervals (CIs) for the cumulative incidence of ICU admission in both groups were estimated using a Cox proportional regression model. The proportional hazards assumption was tested graphically using a log-log plot; there was no evidence to reject the assumption. Similar analyses were done for the ITT, mITT, and mITT-positive populations.

For the secondary outcomes, Kaplan-Meier survival curves were constructed to show clinical improvement, hospital discharge, oxygen requirement, and cumulative mortality over the 14-day period. Adjusted ORs were calculated using the same method used for the primary outcome. There was a single primary hypothesis test. For secondary outcomes, no adjustments for multiplicity were made.

Adverse events were described as absolute and relative frequencies by the type of event. Chi-squared tests were used to evaluate adverse events in the mITT and ITT populations.

Using the eight-point ordinal scale, treatment effect was evaluated at each time point; the frequency of each category in each group was recorded day-by-day and compared with the chi-squared test.

Type of oxygen support, respiratory symptoms, use of concomitant medications, and viral load were analyzed by calculating the percentage difference between groups, with the chi-squared test used to compare treatments day-by-day and the McNemar or Wilcoxon tests to compare changes between days (see Supplementary Material).

The deletion method (pairwise deletion) was used rather than imputation to eliminate missing data; this is particularly advantageous for samples where there is a large volume of data and values can be deleted without significantly distorting the readings. Pairwise deletion is the process of eliminating information when a particular data point, vital for testing, is missing. Pairwise deletion saves more data than likewise deletion because the former only deletes entries where variables were necessary for testing, whereas the latter deletes entire entries if any data are missing, regardless of their importance. FIGURE 1 | Enrolment, randomization, follow-up, and treatment. Five hundred patients were assessed for eligibility at the study sites. Of these, 498 underwent randomization, 2 patients were excluded for not meeting the inclusion criteria. After randomization (n = 249/group), patients were excluded because they were withdrawn by the investigator, had mild/moderate adverse events, were transferred to another hospital, withdrew consent at any time during the study, refused to allow collection of blood and/or nasopharyngeal samples. Therefore, the modified intention-to-treat population consisted of 202 patients in the nitazoxanide group and 203 patients in the placebo group.

Sensitivity analyses were performed to compare variables for the ITT versus the mITT and mITT-positive populations to verify if the process of elimination changed the profile and results.

To evaluate the effects of treatment on ICU admission, forest plots were constructed calculating ORs and 95%CIs for specific subgroups of patients according to the following variables: age, sex, BMI, time from symptom onset until randomization, SpO 2 and chest CT score at day 1, and corticosteroid use during hospitalization.

All statistical analyses were performed in R (16) , and a twotailed p-value < 0.05 was considered significant. Chest CT score, n (%)

Frontiers in Medicine | www.frontiersin.org 

From April 20 to October 2, 2020, 500 patients were assessed for eligibility at the study sites. Two patients did not meet the inclusion criteria; 498 underwent randomization (249 to the nitazoxanide group and 249 to the placebo group), representing the ITT population (Figure 1) . 

In the mITT group, the median age was 56 years [interquartile range (IQR), 46-67 years], 61% were men, 45% represented mixed ethnicity, and 35% were obese ( Table 1) . The median (IQR) number of days from symptom onset to the first dose of nitazoxanide or placebo was 7 (IQR, 5-10 days). The most common comorbidity was hypertension (36%). Patients were on angiotensin-II receptor antagonists (16%) or angiotensinconverting enzyme inhibitors (20%). At day 1, 91% had positive nasopharyngeal swabs. Dry cough and shortness of breath were the most common symptoms and fever (>38 • C) was present in only 7% of patients at hospital admission. All patients received nitazoxanide or placebo as appropriate on the day of randomization. The three populations were well matched according to day 1 characteristics ( 

In the mITT population, at day 14, 20 patients (10%) in the nitazoxanide group were admitted to the ICU requiring invasive mechanical ventilation, and 29 patients (15%) were admitted in the placebo group. The median (95% CI) Kaplan-Meier estimate of need for ICU admission was 13 (12, 13) days for the nitazoxanide group and 12 (11) (12) (13) Of 405 patients, 367 (183 in the nitazoxanide group and 184 in the placebo group) were SARS-CoV-2 RT-PCR positive at enrolment. Viral load on nasopharyngeal swab reduced from day 1 to day 7 in both groups (Supplementary Material). On day 7, the viral load in the mITT-positive population did not reduce significantly in the nitazoxanide group vs. the placebo group (p = 0.083). All patients with negative viral load at baseline remained negative on day 7. Higher viral load at day 1 was associated with a trend toward greater reduction (p = 0.054) in the nitazoxanide group versus the placebo group (Supplementary Material) Primary and secondary outcomes were analyzed in the modified intention-to-treat population. CI, confidence interval; HR, hazard ratio; OR, odds ratio. a Adjusted OR calculated by multiple logistic regression assuming proportional ORs, adjusted for age range (<60 years, ≥60 years), sex, body mass index range (<30 kg/m 2 , ≥30 kg/m 2 ), and time to symptom onset (≤7 days, >7 days). b Hazard ratio was calculated by means of a Cox proportional hazards model according to the moment of analysis.

Frontiers in Medicine | www.frontiersin.org SpO 2 increased over time and differences were observed between the groups on day 3 (Supplementary Material). In the nitazoxanide group, C-reactive protein levels were lower on days 3 and 7 compared to placebo. On day 7, D-dimer, ferritin, and LDH levels were lower in the nitazoxanide vs. placebo group (Supplementary Material).

Lung involvement, as assessed by chest CT score, reduced to a greater extent after nitazoxanide vs. placebo over time (Supplementary Material).

Mild and moderate adverse events were experienced by patients in both groups during the 14-day course of therapy in the mITT and ITT populations ( The most common adverse events were diarrhea, headache, and nausea, with no significant differences between the groups.

Further analysis showed that hospitalized patients who presented with SpO 2 higher than 90% at day 1 and were treated with nitazoxanide were less likely to be admitted to an ICU (OR, 0.17; 95% CI, 0.04-0.75) vs. placebo (Figure 4; Supplementary Material) . Additionally, when corticosteroids were given concomitantly with nitazoxanide, patients were less likely to be admitted to the ICU (OR, 0.45; 95% CI, 0.22-0.96) than placebo recipients who were given corticosteroids. Corticosteroid therapy alone did not affect the ICU admission rate (OR, 1.86; 95% CI, 0.97-3.57) (Figure 4 ; Supplementary Material).

Drug repurposing can reduce the drug development process and allow rapid deployment of effective therapies in a pandemic scenario. In this line, based on the antiviral and anti-inflammatory effects of nitazoxanide (7, 8, 10) , combined with its wide availability, oral administration, and safety, our study evaluated the effects of this therapy in patients hospitalized with COVID-19 pneumonia. Nitazoxanide had no impact on ICU admission due to the need for invasive mechanical ventilation (the primary outcome). Nevertheless, nitazoxanide accelerated symptom resolution, shortened duration of oxygen therapy and reduced levels of inflammatory mediators (secondary outcomes). Due to the low cost and large availability of nitazoxanide, it might be considered in middle-and low-income countries to better control the spread of the pandemic.

The median recovery time was reduced by 1 day with nitazoxanide vs. placebo, which may be associated with decreased pro-inflammatory mediators. Kaplan-Meier timeto-event curves up to day 14 also suggested that clinical improvement and decreased requirement for supplemental oxygen led to earlier discharge in the nitazoxanide group compared with the placebo group. Beneficial effects were mostly observed between days 3 and 7; none were detected on day 14. This may be explained by the fact that nitazoxanide was administered from day 1 to day 5. Further studies are required to evaluate whether different results would be observed by extending the period of nitazoxanide administration. The frequency and severity of adverse events did not differ significantly between the groups, suggesting that nitazoxanide is safe for patients with COVID-19 pneumonia.

In patients with COVID-19 pneumonia undergoing nitazoxanide therapy, 54% of mITT population also received corticosteroids. Interestingly, these patients were less likely to be admitted to the ICU. In the placebo group (55% of mITT population) receiving corticosteroid therapy alone, ICU admission rate was not affected. In the RECOVERY trial (17), patients with COVID-19 pneumonia requiring supplementary oxygen or non-invasive mechanical ventilation treated with dexamethasone alone showed a reduced risk of progression to invasive mechanical ventilation and ICU admission. However, our study was not designed to evaluate corticosteroid therapy alone. Even though dexamethasone is available for patients with COVID-19 pneumonia; there are concerns regarding adverse reactions with its use, particularly reports on hospital-acquired infections, gastrointestinal bleeding, neuromuscular weakness, fungal infections, even with short courses (18) (19) (20) .

In the mITT-positive population, nitazoxanide did not reduce the viral load, which was not attributed to the timing of hospital admission. However, patients with a higher viral load at hospital admission showed a trend toward viral load reduction (p = 0.054) in the nitazoxanide group vs. the placebo group.

In agreement with our findings, Blum et al. (10) described, in a proof-of-concept pilot trial, that nitazoxanide decreased the mean time to hospital discharge, and inflammatory mediators in hospitalized COVID-19 with mild respiratory insufficiency.

Our trial has several challenges: (1) only hospitalized patients in the ward were included. Because there were few beds available, patients remained in the emergency room. Therefore, it took 6 months to complete the study. (2) Online training and monitoring visits were made available to clinicians. (3) Personal protective equipment and some supplies were scarce at the beginning of the trial. (4) Some antivirals such as Remdesivir are not available in the public hospitals.

This study has several limitations. Outcome ascertainment was limited to 14 days after randomization because most patients were discharged before this time point (only 5.9% remained in the hospital). This trial evaluated nitazoxanide as monotherapy for COVID-19, not associated with other antivirals or anti-inflammatory agents (other than corticosteroids after the publication of the RECOVERY trial). Secondary outcomes were underpowered because the study was designed based on the primary outcome; however, this study is a step forward for designing clinical trials to confirm the findings related to the secondary outcomes. The study started in April 2020 when the RT-PCR test was not easily available, therefore we opted to also add a CT scan as an inclusion criterion when cases were highly suggestive of SARS-CoV-2 pneumonia. Concerning the secondary outcomes, in the current study, we opted to focus mainly on respiratory parameters (e.g., respiratory rate, oxygen saturation).

The strengths of our study include the following: (1) randomized, double-blind, and prospective design, the large sample size of patients hospitalized with COVID-19 only in the ward, the enrolment of patients from different parts of Brazil, reflecting different patient characteristics, practice patterns, and health care systems; (2) analyses of ITT and mITT and mITTpositive population; (3) nitazoxanide did not prevent ICU admission; (4) nitazoxanide reduced the recovery time, thus improving clinical outcomes and decreasing the requirement for supplemental oxygen, which reduced the burden on the health care system, potentially increasing hospital capacity.

In patients hospitalized with COVID-19 pneumonia, nitazoxanide, compared with placebo, did not prevent ICU admission, but may accelerate symptom resolution, shorten duration of oxygen therapy and reduce levels of inflammatory mediators. In addition, nitazoxanide demonstrates a good safety profile. Even though vaccination has increased worldwide, some countries are facing a fourth wave. Moreover, countries in Africa, Asia, and Latin America present numerous difficulties and require cheaper drugs to treat COVID-19 pneumonia.

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

The studies involving human participants were reviewed and approved by Brazilian National Commission for Research Ethics (CAAE:30662420.0.1001.0008). The patients/participants provided their written informed consent to participate in this study.

Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2

Clinical characteristics of Coronavirus Disease 2019 in China

Remdesivir for the treatment of Covid-19 -preliminary report

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Early use of nitazoxanide in mild Covid-19 disease: randomised, placebocontrolled trial

Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice

Tizoxanide inhibits inflammation in LPS-activated RAW264.7 macrophages via the suppression of NF-kappaB and MAPK activation

Nitazoxanide superiority to placebo to treat moderate COVID-19 -a pilot prove of concept randomized double-blind clinical trial

A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial

The REDCap consortium: building an international community of software platform partners

Baricitinib plus Remdesivir for hospitalized adults with Covid-19

R: A Language and Environment for Statistical Computing

Dexamethasone in Hospitalized Patients with Covid-19

Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial

Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India

Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?

The authors thank Moira Elizabeth Schöttler (Rio de Janeiro, Brazil) and Lorna O'Brien (authorserv.com) for their assistance in editing the manuscript.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.